These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
474 related items for PubMed ID: 9044847
1. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Stockmeyer B, Valerius T, Repp R, Heijnen IA, Bühring HJ, Deo YM, Kalden JR, Gramatzki M, van de Winkel JG. Cancer Res; 1997 Feb 15; 57(4):696-701. PubMed ID: 9044847 [Abstract] [Full Text] [Related]
2. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM. Cancer Res; 1997 Sep 15; 57(18):4008-14. PubMed ID: 9307286 [Abstract] [Full Text] [Related]
7. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils. Tamamori Y, Sawada T, Nishihara T, Yamashita Y, Ohira M, Ho JJ, Kim YS, Hirakawa-Y S Chung K. Int J Oncol; 2002 Sep 15; 21(3):649-54. PubMed ID: 12168113 [Abstract] [Full Text] [Related]
8. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Akewanlop C, Watanabe M, Singh B, Walker M, Kufe DW, Hayes DF. Cancer Res; 2001 May 15; 61(10):4061-5. PubMed ID: 11358826 [Abstract] [Full Text] [Related]
11. Evaluation of the antibody-dependent cytotoxic capabilities of individual human monocytes. Role of Fc gamma RI and Fc gamma RII and the effects of cytokines at the single cell level. Connor RI, Shen L, Fanger MW. J Immunol; 1990 Sep 01; 145(5):1483-9. PubMed ID: 1696598 [Abstract] [Full Text] [Related]
14. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK. Cancer Res; 1995 Oct 15; 55(20):4586-93. PubMed ID: 7553634 [Abstract] [Full Text] [Related]
15. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Repp R, van Ojik HH, Valerius T, Groenewegen G, Wieland G, Oetzel C, Stockmeyer B, Becker W, Eisenhut M, Steininger H, Deo YM, Blijham GH, Kalden JR, van de Winkel JG, Gramatzki M. Br J Cancer; 2003 Dec 15; 89(12):2234-43. PubMed ID: 14676800 [Abstract] [Full Text] [Related]
16. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Valerius T, Repp R, de Wit TP, Berthold S, Platzer E, Kalden JR, Gramatzki M, van de Winkel JG. Blood; 1993 Aug 01; 82(3):931-9. PubMed ID: 7687898 [Abstract] [Full Text] [Related]
20. Functions of the various IgG Fc receptors in mediating killing of Toxoplasma gondii. Erbe DV, Pfefferkorn ER, Fanger MW. J Immunol; 1991 May 01; 146(9):3145-51. PubMed ID: 1826707 [Abstract] [Full Text] [Related] Page: [Next] [New Search]